ALK-Abelló A/S (AKBLF)
USD 22.05
(0.0%)
USD 22.05
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 765 Million DKK | 9.91% |
| 2022 | 696 Million DKK | -1.97% |
| 2021 | 710 Million DKK | -24.71% |
| 2020 | 943 Million DKK | -4.75% |
| 2019 | 990 Million DKK | 33.42% |
| 2018 | 742 Million DKK | -2.11% |
| 2017 | 758 Million DKK | -2.19% |
| 2016 | 775 Million DKK | 20.16% |
| 2015 | 645 Million DKK | 99.07% |
| 2014 | 324 Million DKK | -0.92% |
| 2013 | 327 Million DKK | -1.51% |
| 2012 | 332 Million DKK | -0.6% |
| 2011 | 334 Million DKK | 595.83% |
| 2010 | 48 Million DKK | 860.0% |
| 2009 | 5 Million DKK | -75.0% |
| 2008 | 20 Million DKK | -71.01% |
| 2007 | 69 Million DKK | -17.86% |
| 2006 | 84 Million DKK | -1.18% |
| 2005 | 85 Million DKK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 518 Million DKK | -32.29% |
| 2024 Q2 | 507 Million DKK | -2.12% |
| 2023 Q3 | 718 Million DKK | -1.64% |
| 2023 Q1 | 639 Million DKK | -8.19% |
| 2023 FY | 765 Million DKK | 9.91% |
| 2023 Q4 | 765 Million DKK | 6.55% |
| 2023 Q2 | 730 Million DKK | 14.24% |
| 2022 Q3 | 653 Million DKK | 1.24% |
| 2022 Q2 | 645 Million DKK | 3.2% |
| 2022 Q1 | 625 Million DKK | -11.97% |
| 2022 FY | 696 Million DKK | -1.97% |
| 2022 Q4 | 696 Million DKK | 6.58% |
| 2021 Q3 | 781 Million DKK | -0.13% |
| 2021 Q4 | 710 Million DKK | -9.09% |
| 2021 FY | 710 Million DKK | -24.71% |
| 2021 Q1 | 944 Million DKK | 0.11% |
| 2021 Q2 | 782 Million DKK | -17.16% |
| 2020 FY | 943 Million DKK | -4.75% |
| 2020 Q1 | 985 Million DKK | -0.51% |
| 2020 Q2 | 971 Million DKK | -1.42% |
| 2020 Q3 | 958 Million DKK | -1.34% |
| 2020 Q4 | 943 Million DKK | -1.57% |
| 2019 Q3 | 950 Million DKK | -0.11% |
| 2019 Q2 | 951 Million DKK | 0.53% |
| 2019 Q4 | 990 Million DKK | 4.21% |
| 2019 Q1 | 946 Million DKK | 27.49% |
| 2019 FY | 990 Million DKK | 33.42% |
| 2018 Q2 | 750 Million DKK | -0.53% |
| 2018 FY | 742 Million DKK | -2.11% |
| 2018 Q3 | 747 Million DKK | -0.4% |
| 2018 Q4 | 742 Million DKK | -0.67% |
| 2018 Q1 | 754 Million DKK | -0.53% |
| 2017 FY | 758 Million DKK | -2.19% |
| 2017 Q3 | 762 Million DKK | -0.52% |
| 2017 Q1 | 771 Million DKK | -0.52% |
| 2017 Q4 | 758 Million DKK | -0.52% |
| 2017 Q2 | 766 Million DKK | -0.65% |
| 2016 Q2 | 635 Million DKK | -0.78% |
| 2016 FY | 775 Million DKK | 20.16% |
| 2016 Q3 | 631 Million DKK | -0.63% |
| 2016 Q4 | 775 Million DKK | 22.82% |
| 2016 Q1 | 640 Million DKK | -0.78% |
| 2015 Q4 | 645 Million DKK | -0.62% |
| 2015 Q1 | 324 Million DKK | 0.0% |
| 2015 Q2 | 655 Million DKK | 102.16% |
| 2015 Q3 | 649 Million DKK | -0.92% |
| 2015 FY | 645 Million DKK | 99.07% |
| 2014 Q1 | 326 Million DKK | -0.31% |
| 2014 Q2 | 326 Million DKK | 0.0% |
| 2014 Q3 | 324 Million DKK | -0.61% |
| 2014 Q4 | 324 Million DKK | 0.0% |
| 2014 FY | 324 Million DKK | -0.92% |
| 2013 Q2 | 330 Million DKK | 0.0% |
| 2013 FY | 327 Million DKK | -1.51% |
| 2013 Q4 | 327 Million DKK | -0.3% |
| 2013 Q3 | 328 Million DKK | -0.61% |
| 2013 Q1 | 330 Million DKK | -0.6% |
| 2012 Q4 | 332 Million DKK | -0.3% |
| 2012 FY | 332 Million DKK | -0.6% |
| 2012 Q1 | 334 Million DKK | 0.0% |
| 2012 Q2 | 333 Million DKK | -0.3% |
| 2012 Q3 | 333 Million DKK | 0.0% |
| 2011 Q4 | 334 Million DKK | 802.7% |
| 2011 Q1 | 49 Million DKK | 2.08% |
| 2011 Q2 | 39 Million DKK | -20.41% |
| 2011 Q3 | 37 Million DKK | -5.13% |
| 2011 FY | 334 Million DKK | 595.83% |
| 2010 Q1 | 45 Million DKK | 800.0% |
| 2010 FY | 48 Million DKK | 860.0% |
| 2010 Q4 | 48 Million DKK | 11.63% |
| 2010 Q3 | 43 Million DKK | -2.27% |
| 2010 Q2 | 44 Million DKK | -2.22% |
| 2009 Q4 | 5 Million DKK | 0.0% |
| 2009 FY | 5 Million DKK | -75.0% |
| 2008 FY | 20 Million DKK | -71.01% |
| 2007 FY | 69 Million DKK | -17.86% |
| 2006 FY | 84 Million DKK | -1.18% |
| 2005 FY | 85 Million DKK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | -1756.661% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -18459.146% |
| SQZ Biotechnologies Company | 27.47 Million USD | -2684.755% |
| Evofem Biosciences, Inc. | 43.37 Million USD | -1663.77% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | -2469.948% |
| Mesoblast Limited | 118.7 Million USD | -544.48% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -80573.141% |
| Genus plc | 233.1 Million USD | -228.185% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -26005.758% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -56837.266% |
| Marizyme, Inc. | 18.71 Million USD | -3987.086% |
| ContraFect Corporation | 2.88 Million USD | -26453.28% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -101900.0% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -564529.817% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -52792.896% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -32789.716% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -13419.835% |
| MultiCell Technologies, Inc. | 202.58 USD | -377628491.174% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | -1230.689% |
| EV Biologics, Inc. | 1.49 Million USD | -51079.093% |
| Q BioMed Inc. | 4.1 Million USD | -18513.225% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | -2211.108% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -121313.732% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -62178.109% |
| Biomind Labs Inc. | 735.54 Thousand USD | -103904.938% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | -345.947% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -5785.976% |
| Skye Bioscience, Inc. | 4.61 Million USD | -16475.426% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -86042.44% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -540467.278% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -12929.948% |
| IMV Inc. | 28.88 Million USD | -2548.534% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -2974354.683% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -33773.824% |
| GB Sciences, Inc. | 1.75 Million USD | -43383.031% |
| Alpha Cognition Inc. | 1.22 Million USD | -62585.804% |
| HST Global, Inc. | 98.31 Thousand USD | -777979.517% |
| CSL Limited | 12.18 Billion USD | 93.721% |
| Halberd Corporation | 150 Thousand USD | -509900.0% |
| Enzolytics Inc. | 996.33 Thousand USD | -76681.173% |
| Resverlogix Corp. | 6.49 Million USD | -11685.549% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -160109.424% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -299205.143% |
| argenx SE | 20 Million USD | -3725.0% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | -1579.104% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -28142.299% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -7481562.592% |
| Genscript Biotech Corporation | 417.73 Million USD | -83.129% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -381225.517% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -31805.257% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -333537.168% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | -1030.94% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -25179.303% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -212571.319% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | -3663.282% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -514517.837% |
| BioStem Technologies, Inc. | 4.71 Million USD | -16137.153% |
| ONE Bio Corp. | 19.71 Million USD | -3780.29% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -305677.394% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -307474.783% |
| Agentix Corp. | 50 Thousand USD | -1529900.0% |
| LadRx Corporation | 33.6 Thousand USD | -2276279.218% |
| Cell Source, Inc. | 9.25 Million USD | -8166.54% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -101063.178% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -101063.178% |
| NovAccess Global Inc. | 2.19 Million USD | -34674.624% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -10716.069% |
| Itoco Inc. | 228.37 Thousand USD | -334872.436% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -362502.204% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -15252.197% |
| Kadimastem Ltd | 891.22 Thousand USD | -85736.814% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -190270.015% |
| CytoDyn Inc. | 30.07 Million USD | -2443.556% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -157865.161% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -217324.051% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -9682.659% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -624389.796% |
| Rebus Holdings, Inc. | 310 Thousand USD | -246674.194% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -16055.321% |
| International Stem Cell Corporation | 4.17 Million USD | -18210.196% |
| Bioxytran, Inc. | 1.92 Million USD | -39640.26% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -1225606.183% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -34977.262% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -9099.134% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -8810.891% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -49080.992% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -285347.761% |
| Neutra Corp. | 54.15 Thousand USD | -1412485.863% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -41703.279% |
| PureTech Health plc | 25.51 Million USD | -2898.589% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -62388.462% |
| IXICO plc | 472.02 Thousand USD | -161968.374% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -4835.165% |
| Gelesis Holdings, Inc. | 62.26 Million USD | -1128.659% |
| CSL Limited | 12.18 Billion USD | 93.721% |
| Cellectis S.A. | 92.77 Million USD | -724.562% |